These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 10824353)
1. Implications of the UKPDS Study for general practice care of type 2 diabetes. Brankin E; Fisher M Br J Gen Pract; 1999 Dec; 49(449):1009. PubMed ID: 10824353 [No Abstract] [Full Text] [Related]
2. [Overviews of fibrate]. Tada N Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141 [No Abstract] [Full Text] [Related]
3. Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk. Duntas L; Kolovou G Future Cardiol; 2011 Mar; 7(2):137-44. PubMed ID: 21453018 [No Abstract] [Full Text] [Related]
4. Evidence-based therapy for type 2 diabetes. The best and worst of times. Flemmer MC; Vinik AI Postgrad Med; 2000 May; 107(5):27-8, 31-4, 37-40, passim. PubMed ID: 10844940 [TBL] [Abstract][Full Text] [Related]
5. [Treatment of blood lipids abnormality in patients with diabetes mellitus]. Wang XM Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Apr; 29(4):379-84. PubMed ID: 19526769 [No Abstract] [Full Text] [Related]
8. Sugar and fat, a recipe for disaster. New guidelines for the pharmacological management of diabetic dyslipidaemia. Tallis GA; Beng C; Popplewell P; Phillips P Aust Fam Physician; 1995 Sep; 24(9):1638-9, 1642-7, 1649. PubMed ID: 7487649 [TBL] [Abstract][Full Text] [Related]
9. The hypolipidemic effect of gemfibrozil on hyperlipidemia in patients with non-insulin-dependent diabetes mellitus. Chang DM; Fuh MM; Jeng CY; Shian LR Taiwan Yi Xue Hui Za Zhi; 1986 May; 85(5):443-50. PubMed ID: 3463653 [No Abstract] [Full Text] [Related]
10. A case for lipid lowering? Response to Dr Paul Durrington. Yudkin JS Diabet Med; 2001 May; Suppl 3():11-2. PubMed ID: 11534306 [No Abstract] [Full Text] [Related]
11. Current and future therapeutic approaches to hyperlipidemia. Farmer JA; Gotto AM Adv Pharmacol; 1996; 35():79-114. PubMed ID: 8920205 [No Abstract] [Full Text] [Related]
12. Lipid disorders in NIDDM: implications for treatment. Taskinen MR; Smith U J Intern Med; 1998 Nov; 244(5):361-70. PubMed ID: 9845851 [TBL] [Abstract][Full Text] [Related]
13. The current status of hypolipidemic drugs. Levy RI; Fredrickson DS Postgrad Med; 1970 Jan; 47(1):130-6. PubMed ID: 5413128 [No Abstract] [Full Text] [Related]
14. Long term improvement in dyslipidaemia in Type 2 diabetes with bezafibrate is not related to changes in insulin resistance. Elkeles RS; Diamond JR; Anyaoku V; Hughes C; Richmond W Atherosclerosis; 1999 Sep; 146(1):195-6. PubMed ID: 10487504 [No Abstract] [Full Text] [Related]
15. Gemfibrozil has antilipemic effects on diabetic patients with hyperlipidemia. Ho LT; Li SH; Chou TY; Liu YF; Perng JC; Han HK; Chen JJ Zhonghua Yi Xue Za Zhi (Taipei); 1987 Jan; 39(1):1-8. PubMed ID: 3484238 [No Abstract] [Full Text] [Related]
16. Treatment of lipids and type 2 diabetes. Hermayer KL Curr Cardiol Rep; 2004 Nov; 6(6):443-50. PubMed ID: 15485606 [TBL] [Abstract][Full Text] [Related]
18. Treatment of lipid disorders in non-insulin-dependent diabetes mellitus. Gylling H; Miettinen TA Curr Opin Lipidol; 1997 Dec; 8(6):342-7. PubMed ID: 9412774 [TBL] [Abstract][Full Text] [Related]
19. Diabetic dyslipidaemia. Australian Diabetes Society position statement. Best JD; Jerums G; Newnham HH; O'Brien RC Med J Aust; 1995 Jan; 162(2):91-3. PubMed ID: 7838034 [No Abstract] [Full Text] [Related]
20. [Tinnitus and lipid metabolism disorders. Value of early normolipemic treatment]. Albertini F Sem Hop Ther; 1977 Apr; 53(4):261-3. PubMed ID: 882873 [No Abstract] [Full Text] [Related] [Next] [New Search]